Back to News
Market Impact: 0.2
OncoHost to Present New Research on Early Detection of Immunotherapy Resistance Using Plasma Proteomics at ISLB 2026
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
New data from OncoHost indicates that longitudinal plasma proteomics may detect disease progression in advanced NSCLC before radiologic assessment and predict overall survival. The excerpt provides no numerical results or additional study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- AI stocks plunge after election, driving down US markets
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition